<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12819">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450723</url>
  </required_header>
  <id_info>
    <org_study_id>UMIAMI-20040015</org_study_id>
    <secondary_id>SCCC-2003161</secondary_id>
    <secondary_id>WIRB-20050911</secondary_id>
    <nct_id>NCT00450723</nct_id>
  </id_info>
  <brief_title>Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer</brief_title>
  <official_title>Thoracoscopic Internal Mammary Sentinel Node Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami Sylvester Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami Sylvester Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as thoracoscopic sentinel lymph node biopsy, may help
      find breast cancer that has spread to lymph nodes between the breasts. It may also help
      doctors plan the best treatment.

      PURPOSE: This clinical trial is studying how well thoracoscopic sentinel lymph node biopsy
      finds sentinel lymph nodes that are located between the breasts in patients with stage I or
      stage II breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the occurrence rate of internal mammary sentinel lymph nodes in patients with
           medially or centrally located stage I or II breast cancer.

        -  Determine the safety, feasibility, and success rate of thorascopic internal mammary
           sentinel lymph node biopsy in these patients.

        -  Determine the rate of metastatic disease in internal mammary sentinel lymph nodes
           obtained thoracoscopically in these patients.

      OUTLINE: Patients undergo standard axillary sentinel lymph node dissection during surgery
      (i.e., lumpectomy or mastectomy). Patients receive a radioactive tracer (i.e., technetium Tc
      99m sulfur colloid) and isosulfan blue by peritumoral injection for identification of the
      axillary and internal mammary sentinel lymph nodes (IMSLN). Identified axillary sentinel
      lymph nodes are dissected. Identified IMSLNs are removed through the lumpectomy/mastectomy
      incision, if accessible. If they are not accessible, patients undergo thorascopic IMSLN
      biopsy to remove the nodes.

      All removed sentinel lymph nodes (axillary or internal mammary) are examined for gross and
      microscopic carcinoma for future therapy planning.

      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Metastatic Disease in Internal Mammary Sentinel Lymph Nodes</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Identifiable Internal Mammary Sentinel Lymph Nodes</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Sentinel Lymph Node Biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosulfan blue</intervention_name>
    <description>Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.</description>
    <arm_group_label>Sentinel Lymph Node Biopsy</arm_group_label>
    <other_name>Lymphazurin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary Lymph Node Dissection</intervention_name>
    <description>Axillary Lymph Node Dissection</description>
    <arm_group_label>Sentinel Lymph Node Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.</description>
    <arm_group_label>Sentinel Lymph Node Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel Lymph Node Biopsy</intervention_name>
    <description>Sentinel Lymph Node Biopsy</description>
    <arm_group_label>Sentinel Lymph Node Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracoscopic Surgery</intervention_name>
    <description>Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.</description>
    <arm_group_label>Sentinel Lymph Node Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Technetium Tc 99m Sulfur Colloid</intervention_name>
    <description>Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots</description>
    <arm_group_label>Sentinel Lymph Node Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed breast cancer

               -  Stage I or II disease (T1-T2, N0, M0/MX disease)

                    -  No chest wall invasion by tumor (T3 disease)

          -  Medially or centrally located lesion

          -  No multicentric disease

               -  Multifocal disease allowed

          -  No clinically positive axillary nodes

          -  No enlarged internal mammary nodes by CT scan

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Male or female

          -  Menopausal status not specified

          -  American Society of Anesthesiologists (ASA) physical status classification 1-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No other concurrent known, invasive malignancy

          -  No known chronic pulmonary disease

          -  No known allergy to methylene blue or isosulfan blue

        PRIOR CONCURRENT THERAPY:

          -  No prior thoracic or cardiac surgery

          -  No prior ipsilateral chest tube placement

               -  Contralateral chest tube placement allowed

          -  No prior neoadjuvant chemotherapy

          -  No prior radiotherapy to the mediastinum
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eli Avisar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Avisar E, Molina MA, Scarlata M, Moffat FL. Internal mammary sentinel node biopsy for breast cancer. Am J Surg. 2008 Oct;196(4):490-4. doi: 10.1016/j.amjsurg.2008.06.003. Epub 2008 Aug 23.</citation>
    <PMID>18723148</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>July 25, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2007</firstreceived_date>
  <firstreceived_results_date>January 22, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 2001 and 2007 a prospective database was obtained of all patients undergoing internal mammary sentinel lymph node biopsies using an open or thoracoscopic approach. Radiotracer injection was peritumoral.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sentinel Lymph Node Biopsy</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50" lower_limit="32" upper_limit="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy</title>
        <time_frame>5 years</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sentinel Lymph Node Biopsy</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Metastatic Disease in Internal Mammary Sentinel Lymph Nodes</title>
        <time_frame>5 years</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sentinel Lymph Node Biopsy</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Rate of Metastatic Disease in Internal Mammary Sentinel Lymph Nodes</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Identifiable Internal Mammary Sentinel Lymph Nodes</title>
        <time_frame>5 years</time_frame>
        <safety_issue>No</safety_issue>
        <population>Of the 39 patients enrolled, 34 had identifiable internal mammary sentinel lymph nodes.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentinel Lymph Node BIopsy</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With Identifiable Internal Mammary Sentinel Lymph Nodes</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A total of 39 subjects were enrolled however; only 34 of the subjects had identifiable internal mammary sentinel lymph nodes. As a result, the data of 34 subjects were analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eli Avisar MD</name_or_title>
      <organization>UM/Sylvester Comprehensive Cancer Center</organization>
      <phone>305-243-4902</phone>
      <email>eavisar@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
